It is currently unclear if our anti-HER3 mAb 4A7 may be able to enhance the efficacy of other commonly used chemotherapeutic agents in TNBC, including doxorubicin, cyclophosphamide, 5-Fu, etc. The development of HER3 Ab-drug conjugates (ADCs) provides a new avenue to identify more effective HER3-targeted therapy for human cancers [26, 30, 74]. The gene discussed is ERBB3; the disease is cancer.